Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SAFC, a member of the Sigma-Aldrich Group, has expanded its Jerusalem, Israel facility which further expands the company's contract manufacturing capabilities in large molecule recombinant proteins and small molecule active pharmaceutical ingredients (APIs) through fermentation, including high potent APIs (HPAPIs) and secondary metabolites.
Subscribe to our email newsletter
SAFC’s 50,000 sqft cGMP fermentation expansion, which is expected to begin production in October 2010, will focus on niche fermentation of APIs and bulk drugs, producing secondary metabolites (antibiotic-like molecules), cytotoxins and large-molecule proteins.
SAFC said that the 30,000 sqft area of the new facility has been designed to be Biosafety Level 2 compliant – enabling manipulation of human pathogens.
Capabilities include 1,000 and 4,000-liter tank capacities for bacterial and fungal fermentation, as well as explosion-proof suites.
SAFC president Gilles Cottier said that fermentation is a technology, yet new applications have been recently discovered, including the synthesis of high potency compounds.
“The Jerusalem expansion builds upon over 30 years of Sigma-Aldrich experience in the development and manufacture microbial-derived products,” Cottier said.
“The site is a full-service facility offering purification and analytical expertise associated with fermentation technology such as microbiology, organic chemistry, biochemistry and molecular biology.”